
Real Estate · Health Care REITs
$81.63
-0.63%
Vol: 3.8M
Friday, June 19, 2026
No material news in the last 48 hours.
On June 16, 2026, Raymond James reinstated coverage of Ventas with an Outperform rating and a $94 price target. The analyst highlighted the REIT's senior housing operating portfolio, pointing to rising occupancy and improving profit margins as key drivers. The call followed Ventas's upbeat Nareit REITweek investor presentation in early June, where it shared a positive 2026 outlook and reaffirmed its ~$0.52 quarterly dividend payable in July. The combination of constructive analyst sentiment and reaffirmed guidance helped reverse a prior six-day share slide. The risk is that senior-housing recovery momentum and occupancy gains are already partly reflected after the rebound, leaving limited room for upside surprises.
No material news in the last 48 hours.
No material news in the last 48 hours.
No material news in the last 48 hours.
No material news in the last 48 hours.
Ventas filed Amendment No. 3 to its ATM Sales Agreement on May 15, 2026, increasing aggregate gross sales price to $3.0 billion. 2026 Annual Meeting held May 13 with all 12 director nominees elected and KPMG ratified. Executive Peter Bulgarelli retired May 1 with separation agreement. Multiple analysts raised price targets: Goldman Sachs to $110 (from $100) on May 15, Jefferies to $100 (from $97) on May 12.
Ventas filed Amendment No. 3 to its ATM sales agreement on May 15, expanding the at-the-market equity program capacity to $3.0B in common stock issuance, signaling intent to fund continued senior housing growth via equity. The 2026 Annual Meeting on May 13 saw all 12 directors elected and KPMG ratified with strong support. Multiple analyst price target hikes followed Q1 strength: Goldman Sachs raised to $110 from $100 (May 15), Jefferies to $100 from $97 (May 12), JPMorgan to $94 from $93 (May 11), and KeyBanc to $95 from $90 (May 7). The stock hit an all-time high of $91.06 on May 15 after Q1 2026 normalized FFO of $0.94 (+9% YoY), a dividend hike to $0.52/share, and raised full-year guidance ($3.78-$3.88). Risks: increased equity issuance could pressure shares near-term, and rising rates remain a headwind for REITs at peak valuations.
On May 15, 2026, Ventas amended its ATM sales agreement to $3.0B aggregate capacity to support senior housing growth. Q1 2026 normalized FFO rose 9% to $0.94, with dividend raised to $0.52 quarterly ($2.08 annualized) from $0.48. Stock reached all-time high $91.06 on May 15. 2026 Annual Meeting on May 13 saw all 12 directors elected and KPMG ratified. Jefferies raised PT to $100 from $97 (May 12); JPMorgan to $94 from $93 (May 11). Bear case: $3B equity program could dilute if deployed aggressively; senior housing supply could pressure rents.
Ventas entered Amendment No. 3 to its ATM Sales Agreement on May 15, 2026, increasing the aggregate gross sales price of common stock available for issuance under the program to $3,000,000,000. The expansion gives the REIT greater flexibility to fund senior housing investments amid strong Q1 momentum (22% revenue growth, raised FFO guidance to $3.82-$3.89). At the 2026 Annual Meeting held May 13, all 12 director nominees were elected and executive compensation received advisory approval. The company also disclosed a separation agreement with executive Peter J. Bulgarelli tied to his May 1 retirement. Multiple analysts including Jefferies have raised price targets into the $93-$100 range. Sentiment is moderately positive on senior housing demand strength.
Ventas declared a $0.52 quarterly common dividend on May 13, payable July 16 to holders of record June 30. The stock hit an all-time high of $87.24 supported by Q1 2026 results showing revenue up 22% YoY, EPS of $0.94 (beating $0.91 estimate), SHOP NOI up 15%+, and a raised FY FFO guidance to $3.82-$3.89 per share. Senior housing demand and occupancy gains continue to fuel positive analyst sentiment. KeyBanc raised PT to $95 (Overweight) and Jefferies raised to $100 (Buy). Risk: shares already near consensus average PT of $90.46, limiting near-term upside.
Ventas declared a quarterly dividend of $0.52 per common share on May 13, 2026, payable July 16 to stockholders of record June 30. The REIT beat Q1 2026 estimates with EPS of $0.94 (vs $0.91 consensus) and reported 22% YoY revenue growth and an 83% rise in net income, driven by strong senior housing fundamentals. Management raised full-year FFO guidance to $3.82-$3.89 per share and emphasized a strategic shift toward regional operators in senior housing. The stock has reached an all-time high near $87.42, up 33.66% over the past year and 6.25% week-over-week. According to 13 analysts, the consensus rating is Buy with a 12-month price target of $90.46. Multiple analysts raised their targets following the Q1 results.
Ventas reported strong Q1 2026 results that beat expectations, with revenue up 22% YoY to $1.66 billion and normalized FFO per share up 9% to $0.94. The healthcare REIT raised its quarterly dividend to $0.52/share ($2.08 annualized) from $0.48 and lifted full-year FFO guidance to $3.82-$3.89 per share. Investment guidance for 2026 was raised to $3 billion focused on senior housing (up from $2.5 billion), with $1.7 billion already completed YTD through April. The 15% NOI growth in the senior housing operating portfolio (SHOP) drove performance. KeyBanc raised its price target to $95 from $90 with an Overweight rating, and consensus target is $93.56. The stock hit an all-time high of $87.20 and shares rose approximately 1.9% on the earnings release date.
Ventas Q1 2026 revenue rose 22% YoY to $1.66B and normalized FFO/share grew 9% to $0.94, driven by strength in its SHOP (senior housing) portfolio. Management raised FY26 FFO guidance to $3.82-$3.89. Analyst PT increases: KeyBanc to $95 from $90 (May 7), BMO to $100 from $93 (May 4), RBC to $98 from $91 (May 4). Stock hit all-time high of $87.20 on May 8. Swedbank AB increased its VTR stake by 7.8% in Q4. YTD return ~13.82% with 30-day return of 7.33%.
| Company | Price | Day | 1M | Fwd P/E | Beta | Mkt Cap |
|---|---|---|---|---|---|---|
| WELLWELLTOWER | $206.76 | +0.10% | -5.5% | 61.5x | 0.78 | $145.9B |
| VTRVENTAS | $81.63 | -0.63% | -7.9% | 96.4x | 0.73 | $39.7B |
| DOCHEALTHPEAK | $19.57 | +0.88% | -0.5% | 130.4x | 1.03 | $13.5B |
| PLDPROLOGIS | $140.80 | -0.10% | -2.9% | 41.9x | 1.33 | $131.7B |
| EQIXEQUINIX | $1,092.30 | +0.35% | +2.5% | 56.8x | 0.97 | $107.7B |
| AMTAMERICAN | $175.68 | -2.99% | -4.3% | 25.5x | 0.89 | $82.0B |
Price between 50d and 200d. Testing 50d support.